EGFR (Epidermal growth factor receptor)

Multiplex immunofluorescence staining demonstrated that BCL-xL inhibition effectively triggered apoptosis in heterogeneous PDX tumor slice models, including models harboring oncogenic BRAF mutations. Our findings suggest that cetuximab-resistant CRC retains apoptotic competence, and that BCL-xL inhibition serves as a robust alternative therapeutic strategy that is largely independent of the tumor mutational profile.

P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | N=20 --> 30

P2, N=107, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

Compared to results from established architectures such as Inception-v3 on the same WSIs, our model demonstrated significantly improved performance for most features. With further optimization, our model could support triaging for molecular testing and inform precision treatment strategies for NS-LUAD patients.

Molecular docking and dynamics simulations indicated stable, favorable binding within the ATP-binding sites of both kinases. Collectively, these findings identify compound (11a) as a promising dual-target anticancer lead warranting further preclinical investigation.

A few were predicted to be carcinogenic, immunotoxic, and/or cytotoxic. Overall, the clerodane-type furano-diterpenoids from T. crispa show encouraging results in in-silico studies and may be considered for further modification and lead development.

P1, N=21, Recruiting, Marcela V. Maus, M.D.,Ph.D. | Trial primary completion date: Jun 2026 --> Sep 2026 | Trial completion date: Jun 2027 --> Sep 2027

Regional enrollment should be viewed not as a regulatory formality, but as a scientific and ethical priority. The future of global oncology trials hinges on proactive regional planning, innovative methodology, and cross-sector collaboration. Aligning global efficiency with local relevance can enhance scientific robustness, support regulatory alignment, and expand equitable access to novel cancer therapies worldwide.

Major challenges include heterogeneity and temporal variability of TAA expression, cytokine release syndrome (CRS) mitigation strategies, pharmacodynamic optimization, and delivery methods to maximize tumor bioavailability while limiting systemic toxicity. This review details the molecular mechanisms, preclinical evidence, clinical trial outcomes, and translational challenges for BsAbs in breast cancer, highlighting their transformative potential in expanding immunotherapeutic efficacy beyond current limitations.

Our findings suggest that PD-L1 immunohistochemistry is effective for evaluating pleural fluid cytological specimens and that PD-L1 expression is significantly higher in lung adenocarcinoma patients with malignant pleural effusions associated with the KRAS, ALK and BRAF mutations.

A 72-year-old man with metastatic lung adenocarcinoma (epidermal growth factor receptor (EGFR) exon 19 del) progressing on osimertinib initiated treatment with amivantamab, pemetrexed, and carboplatin. Early recognition, based on clinical suspicion and characteristic cytokine profiles, and differentiation from infection are crucial. The concurrent rapid tumor response indicates that effective immune activation drives both toxicity and efficacy, underscoring the need for optimal management strategies to mitigate CRS without compromising antitumor activity.

These cases indicate that prompt recognition of MUO and early ureteral decompression may meaningfully improve symptoms and preserve renal function, thereby contributing to favorable clinical trajectories in selected long-term survivors. As patient survival continues to lengthen with modern systemic therapies, optimizing drainage strategies will become increasingly important.